By IDSE News Staff
The FDA approved the first fecal microbiota product (Vowst, Seres Therapeutics) that is taken orally to prevent recurrent Clostridioides difficile infection (rCDI) in people who are 18 years of age and older, following antibacterial treatment for rCDI.
“Today’s approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection,” said Peter Marks, MD, PhD, the director of the FDA’s Center for Biologics